arrow
J

Julie Lyng Forman

University of Copenhagen
H指数:42
被引数:7,183

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Associations between work stressors, measured by the demand-control-support and effort-reward-imbalance models, and diurnal cortisol concentrations in saliva

工作压力源(通过需求-控制-支持模型和努力-回报失衡模型测量)与唾液日皮质醇浓度的关联

2026-09-090
OAAI
Risk of minor congenital heart defect in infants conceived via assisted reproductive technology: cohort study from the Copenhagen Baby Heart Study

通过辅助生殖技术受孕婴儿发生轻微先天性心脏缺陷的风险:哥本哈根婴儿心脏研究队列研究

2026-08-010
OAAI
Randomized controlled single-center clinical trial of high-intensity interval training in patients with systemic lupus erythematosus

系统性红斑狼疮患者高强度间歇训练的单中心随机对照临床试验

2026-07-010
OAAI
The VIA Family 2.0 study: a randomized clinical trial evaluating a family-based intervention for children born to parents with mental illnesses-study protocol

VIA家庭研究2.0:一项评估针对父母患有精神疾病儿童的家庭干预的随机临床试验-研究方案

2026-05-010
PRE
The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial

恩格列净(empagliflozin)对超重且具有心力衰竭高风险的老年个体左心室质量和容积的影响:Empire Prevent 心脏试验

2026-03-120
OAAI
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial

达匹鲁肽(Dapiglutide),一种GLP-1和GLP-2受体双重激动剂,用于肥胖症:一项随机、双盲、安慰剂对照的平行组概念验证试验

2026-02-210
OAAI
Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial

恩格列净在心力衰竭高风险患者中的疗效:EMPIRE PREVENT代谢试验

2026-02-010
PRE
Optimising the protocol for modified natural cycle frozens embryo transfer (mNC-FET): a multicentre, single-blinded randomised controlled trial

优化改良自然周期冻胚移植(mNC-FET)方案:一项多中心、单盲随机对照试验

2026-01-130
OA
Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multi-centre RCT

新诊断的格雷夫斯氏甲亢患者中硒补充剂的应用:一项双盲、多中心随机对照试验

2026-01-011
PRE
No Effect of Low-Dose Aspirin Versus Placebo as Add-On Treatment in Bipolar Disorder-Results From a Randomised Controlled Trial (the A-Bipolar RCT)

低剂量阿司匹林与安慰剂作为附加治疗在双相障碍中的效果无差异——随机对照试验(A-Bipolar RCT)结果

2025-11-010
OAAI
Five years liraglutide treatment improves glucose tolerance in women with previous gestational diabetes mellitus-Results from a randomised controlled trial

五年利拉鲁肽治疗改善了既往妊娠期糖尿病女性的葡萄糖耐量——随机对照试验结果

2025-11-010
PRE
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial

利妥昔单抗用于减少1型糖尿病残余炎症风险的再利用:REC1TE试验的设计与原理

2025-10-060
OAAI
Intravenous Arginine Stimulates Glucagon Secretion More Than Equimolar Alanine, Leucine, Glutamine, and Proline in Humans

静脉注射精氨酸比等摩尔量的丙氨酸、亮氨酸、谷氨酰胺和脯氨酸更能刺激人类胰高血糖素分泌。

2025-10-010
OAAI
Cardiometabolic function in Offspring, Mother and Placenta after Assisted Reproductive Technology (COMPART): a prospective cohort study

辅助生殖技术对后代、母体和胎盘的心代谢功能的影响(COMPART):一项前瞻性队列研究

2025-09-150
OA
Exploring the Role of Cardiac Troponin-Specific Autoantibodies: Prolonged Cardiac Troponin Elimination, Reduced Clearance, and Variable Interference across 5 Commercial Assays

探索心肌肌钙蛋白-S特异性自身抗体作用:心肌肌钙蛋白消除延长、清除率降低及在5种商业检测试剂盒中的可变干扰

2025-07-150
OAAI
Investigation of malondialdehyde as a trait marker associated with familial risk in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives-A longitudinal cohort study

调查丙二醛作为与家族风险相关的特征标志物在 newly diagnosed 双相障碍患者及其未受影响的一级亲属中的纵向队列研究

2025-06-010
PRE